Source - RNS
RNS Number : 3860L
Sinclair Pharma PLC
30 September 2016



Sinclair Pharma plc




London, 30 September 2016 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company"): In accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, Sinclair confirms that the Company's issued share capital consists of 502,089,508 ordinary shares of 1p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure and Transparency Rules.


For further information, please contact:


Sinclair Pharma plc                                                            Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Andy Crane



Peel Hunt LLP (Nominated Adviser)                                  Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson      


Notes to Editors:

About Sinclair Pharma plc 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributorsFor more information, please visit


This information is provided by RNS
The company news service from the London Stock Exchange